BioTime, Inc. (BTX) Scheduled to Post Quarterly Earnings on Wednesday
BioTime, Inc. (NYSEMKT:BTX) will announce its earnings results after the market closes on Wednesday, November 1st.
Shares of BioTime, Inc. (NYSEMKT BTX) opened at 2.47 on Wednesday. BioTime, Inc. has a 1-year low of $2.47 and a 1-year high of $3.96. The firm’s 50-day moving average price is $2.78 and its 200 day moving average price is $2.96. The company has a market capitalization of $286.04 million, a PE ratio of 4.15 and a beta of 1.37.
COPYRIGHT VIOLATION WARNING: “BioTime, Inc. (BTX) Scheduled to Post Quarterly Earnings on Wednesday” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/25/biotime-inc-btx-scheduled-to-post-quarterly-earnings-on-wednesday.html.
In other BioTime news, Director Broadwood Partners, L.P. purchased 10,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was acquired at an average cost of $2.60 per share, with a total value of $26,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 2,866,203 shares of company stock valued at $7,481,218 over the last three months.
BTX has been the subject of a number of recent analyst reports. ValuEngine lowered shares of BioTime from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of BioTime from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research report on Tuesday, July 18th. Finally, BidaskClub lowered shares of BioTime from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. BioTime has a consensus rating of “Hold” and a consensus target price of $5.33.
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.